1.1 	A bill for an act
1.2 	relating to health; establishing an opiate epidemic response; establishing an Opiate 
1.3 	Epidemic Response Advisory Council; establishing an opiate epidemic response 
1.4 	account; establishing an opiate manufacturer and wholesale drug distributor 
1.5 	registration fee to fund the opiate epidemic response account; requiring a prescriber 
1.6 	to access the prescription monitoring program before prescribing a controlled 
1.7 	substance; limiting the quantity of opiates and narcotics that can be prescribed for 
1.8 	acute pain at any one time; requiring a report; appropriating money; amending 
1.9 	Minnesota Statutes 2018, sections 151.01, subdivision 27; 151.252, subdivision 
1.10 	1; 151.47, by adding a subdivision; 152.105, subdivision 2; 152.11, subdivisions 
1.11 	1, 2, 4; 152.126, subdivisions 6, 10; 214.12, by adding a subdivision; Laws 2017, 
1.12 	First Special Session chapter 6, article 10, section 144; proposing coding for new 
1.13 	law in Minnesota Statutes, chapters 151; 256.
1.14 	BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

1.15 	ARTICLE 1
1.16 	OPIATE EPIDEMIC RESPONSE

1.17 	Section 1. [151.066] OPIATE PRODUCT REGISTRATION FEE.
1.18 		Subdivision 1.Definition. (a) For purposes of this section, the following terms have the 
1.19 	meanings given to them in this subdivision.
1.20 	(b) "Manufacturer" means a manufacturer licensed under section 151.252 that is engaged 
1.21 	in the manufacturing of an opiate.
1.22 	(c) "Opiate" means any opiate-containing controlled substance listed in section 152.02, 
1.23 	subdivisions 3 to 5, that is distributed, delivered, sold, or dispensed into or within this state.
1.24 	(d) "Wholesaler" means a wholesale drug distributor who is licensed under section 
1.25 	151.47, and is engaged in the wholesale drug distribution of an opiate.
2.1 		Subd. 2.Reporting requirements. (a) By March 1 of each year, beginning March 1, 
2.2 	2020, each manufacturer and each wholesale drug distributor must report to the board every 
2.3 	sale, delivery, or other distribution within or into this state of any opiate that is made to any 
2.4 	practitioner, pharmacy, hospital, veterinary hospital, or other person who is permitted by 
2.5 	section 151.37 to possess controlled substances for administration or dispensing to patients 
2.6 	that occurred during the previous calendar year. Reporting must be in the automation of 
2.7 	reports and consolidated orders system format unless otherwise specified by the board. If 
2.8 	a manufacturer or wholesaler fails to provide information required under this paragraph on 
2.9 	a timely basis, the board may assess an administrative penalty of $100 per day. This penalty 
2.10 	shall not be considered a form of disciplinary action.
2.11 	(b) By March 1 of each year, beginning March 1, 2020, each owner of a pharmacy with 
2.12 	at least one location within this state must report to any board the intracompany delivery 
2.13 	or distribution into this state, of any opiate, to the extent that those deliveries and distributions 
2.14 	are not reported to the board by a licensed wholesale drug distributor owned by, under 
2.15 	contract to, or otherwise operating on behalf of the owner of the pharmacy. Reporting must 
2.16 	be in the manner and format specified by the board for deliveries and distributions that 
2.17 	occurred during the previous calendar year.
2.18 		Subd. 3.Determination of each manufacturer's registration fee. (a) The board shall 
2.19 	annually assess manufacturer registration fees that in an aggregate amount total $12,000,000. 
2.20 	The board shall determine each manufacturer's annual registration fee that is prorated and 
2.21 	based on the manufacturer's percentage of the total number of units reported to the board 
2.22 	under subdivision 2.
2.23 	(b) Notwithstanding paragraph (a), no annual registration fee shall be greater than 
2.24 	$500,000 or less than $5,000.
2.25 	(c) By April 1 of each year, beginning April 1, 2020, the board shall notify each 
2.26 	manufacturer of the annual amount of the manufacturer's registration fee to be paid by June 
2.27 	1, in accordance with section 151.252, subdivision 1, paragraph (b).
2.28 	(d) In conjunction with the data reported under this section, and notwithstanding section 
2.29 	152.126, subdivision 6, the board may use the data reported under section 152.126, 
2.30 	subdivision 4, to determine the manufacturer registration fees required under this subdivision.
2.31 	(e) A manufacturer may dispute the registration fee as determined by the board no later 
2.32 	than 30 days after the date of notification. However, the manufacturer must still remit the 
2.33 	fee as required by section 151.252, subdivision 1, paragraph (b). The dispute must be filed 
2.34 	with the board in the manner and using the forms specified by the board. A manufacturer 
3.1 	must submit, with the required forms, data satisfactory to the board that demonstrates that 
3.2 	the registration fee was incorrect or otherwise unwarranted. The board must make a decision 
3.3 	concerning a dispute no later than 60 days after receiving the required dispute forms. If the 
3.4 	board determines that the manufacturer has satisfactorily demonstrated that the original fee 
3.5 	was incorrect, the board must: (1) adjust the manufacturer's registration fee; (2) adjust the 
3.6 	manufacturer's registration fee due the next year by the amount that is in excess of the correct 
3.7 	fee that should have been paid; or (3) refund the amount paid in error.
3.8 		Subd. 4.Determination of each wholesaler's registration fee. (a) The board shall 
3.9 	annually assess wholesaler registration fees that in an aggregate amount total $8,000,000. 
3.10 	The board shall determine each wholesaler's annual registration fee that is prorated and 
3.11 	based on the wholesaler's percentage of the total number of units reported to the board under 
3.12 	subdivision 2. This paragraph does not apply to a wholesaler if the wholesaler is also licensed 
3.13 	as a drug manufacturer under section 151.252.
3.14 	(b) By April 1 of each year, beginning April 1, 2020, the board shall notify each 
3.15 	wholesaler, the annual amount of the wholesaler's registration fee to be paid by June 1, in 
3.16 	accordance with section 151.47, subdivision 1a.
3.17 	(c) In conjunction with the data reported under this section, and notwithstanding section 
3.18 	152.126, subdivision 6, the board may use the data reported under section 152.126, 
3.19 	subdivision 4, to determine the wholesaler registration fees required under this subdivision.
3.20 	(d) A wholesaler may dispute the registration fee as determined by the board no later 
3.21 	than 30 days after the date of notification. However, the wholesaler must still remit the fee 
3.22 	as required by section 151.47, subdivision 1a. The dispute must be filed with the board in 
3.23 	the manner and using the forms specified by the board. A wholesaler must submit, with the 
3.24 	required forms, data satisfactory to the board that demonstrates that the registration fee was 
3.25 	incorrect. The board must make a decision concerning a dispute no later than 60 days after 
3.26 	receiving the required dispute forms. If the board determines that the wholesaler has 
3.27 	satisfactorily demonstrated that the original fee was incorrect, the board must adjust the 
3.28 	wholesaler's registration fee due the next year by the amount that is in excess of the correct 
3.29 	fee that should have been paid.
3.30 		Subd. 5.Report. (a) The Board of Pharmacy shall evaluate the registration fee on drug 
3.31 	manufacturers and wholesalers established under this section, and whether the fee has 
3.32 	impacted the prescribing practices for opiates by reducing the number of opiate prescriptions 
3.33 	issued during calendar years 2020, 2021, and 2022, to the extent the board has the ability 
3.34 	to effectively identify a correlation. Notwithstanding section 152.126, subdivision 6, the 
4.1 	board may access the data reported under section 152.126, subdivision 4, to conduct this 
4.2 	evaluation.
4.3 	(b) The board shall submit the results of its evaluation to the chairs and ranking minority 
4.4 	members of the legislative committees with jurisdiction over health and human services 
4.5 	policy and finance by March 1, 2023.
4.6 		Subd. 6.Legislative review. The legislature shall review the reports from the Opiate 
4.7 	Epidemic Response Advisory Council under section 256.042, subdivision 5, paragraph (a), 
4.8 	the reports from the commissioner of management and budget on the Results First evaluation 
4.9 	activities under section 256.042, subdivision 5, paragraph (b), the report from the Board of 
4.10 	Pharmacy under subdivision 5, and any other relevant report or information related to the 
4.11 	opioid crisis in Minnesota, to make a determination about whether the opiate product 
4.12 	registration fee assessed under this section should continue beyond July 1, 2023.

4.13 	Sec. 2. Minnesota Statutes 2018, section 151.252, subdivision 1, is amended to read:
4.14 		Subdivision 1.Requirements. (a) No person shall act as a drug manufacturer without 
4.15 	first obtaining a license from the board and paying any applicable fee specified in section 
4.16 	151.065.
4.17 	(b) In addition to the license required under paragraph (a), a manufacturer of a Schedules 
4.18 	II through IV opiate controlled substance must pay the applicable registration fee specified 
4.19 	in section 151.066, subdivision 3, by June 1 of each year, beginning June 1, 2020. In the 
4.20 	event of a change of ownership of the manufacturer, the new owner must pay the registration 
4.21 	fee specified under section 151.066, subdivision 3, that the original owner would have been 
4.22 	assessed had the original owner retained ownership. The registration fee collected under 
4.23 	this paragraph shall be deposited in the opiate epidemic response account established under 
4.24 	section 256.043.
4.25 	(b) (c) Application for a drug manufacturer license under this section shall be made in 
4.26 	a manner specified by the board.
4.27 	(c) (d) No license shall be issued or renewed for a drug manufacturer unless the applicant 
4.28 	agrees to operate in a manner prescribed by federal and state law and according to Minnesota 
4.29 	Rules.
4.30 	(d) (e) No license shall be issued or renewed for a drug manufacturer that is required to 
4.31 	be registered pursuant to United States Code, title 21, section 360, unless the applicant 
4.32 	supplies the board with proof of registration. The board may establish by rule the standards 
5.1 	for licensure of drug manufacturers that are not required to be registered under United States 
5.2 	Code, title 21, section 360.
5.3 	(e) (f) No license shall be issued or renewed for a drug manufacturer that is required to 
5.4 	be licensed or registered by the state in which it is physically located unless the applicant 
5.5 	supplies the board with proof of licensure or registration. The board may establish, by rule, 
5.6 	standards for the licensure of a drug manufacturer that is not required to be licensed or 
5.7 	registered by the state in which it is physically located.
5.8 	(f) (g) The board shall require a separate license for each facility located within the state 
5.9 	at which drug manufacturing occurs and for each facility located outside of the state at 
5.10 	which drugs that are shipped into the state are manufactured.
5.11 	(g) (h) The board shall not issue an initial or renewed license for a drug manufacturing 
5.12 	facility unless the facility passes an inspection conducted by an authorized representative 
5.13 	of the board. In the case of a drug manufacturing facility located outside of the state, the 
5.14 	board may require the applicant to pay the cost of the inspection, in addition to the license 
5.15 	fee in section 151.065, unless the applicant furnishes the board with a report, issued by the 
5.16 	appropriate regulatory agency of the state in which the facility is located or by the United 
5.17 	States Food and Drug Administration, of an inspection that has occurred within the 24 
5.18 	months immediately preceding receipt of the license application by the board. The board 
5.19 	may deny licensure unless the applicant submits documentation satisfactory to the board 
5.20 	that any deficiencies noted in an inspection report have been corrected.

5.21 	Sec. 3. Minnesota Statutes 2018, section 151.47, is amended by adding a subdivision to 
5.22 	read:
5.23 		Subd. 1a.Controlled substance wholesale drug distributor requirements. In addition 
5.24 	to the license required under subdivision 1, a wholesale drug distributor distributing a  
5.25 	Schedules II through IV opiate controlled substance must pay the applicable registration 
5.26 	fee specified in section 151.066, subdivision 4, by June 1 of each year, beginning June 1, 
5.27 	2020. In the event of a change in ownership of the wholesale drug distributor, the new owner 
5.28 	must pay the registration fee specified in section 151.066, subdivision 4, that the original 
5.29 	owner would have been assessed had the original owner retained ownership. The registration 
5.30 	fee collected under this subdivision shall be deposited in the opiate epidemic response 
5.31 	account established under section 256.043.

6.1 	Sec. 4. [256.042] OPIATE EPIDEMIC RESPONSE ADVISORY COUNCIL.
6.2 		Subdivision 1.Establishment of the advisory council. (a) The Opiate Epidemic 
6.3 	Response Advisory Council is established to develop and implement a comprehensive and 
6.4 	effective statewide effort to address the opioid addiction and overdose epidemic in Minnesota. 
6.5 	The council shall focus on:
6.6 	(1) prevention and education, including public education and awareness for adults and 
6.7 	youth, prescriber education, the development and sustainability of opioid overdose prevention 
6.8 	and education programs, and providing financial support to local law enforcement agencies 
6.9 	for opiate antagonist programs;
6.10 	(2) treatment, including statewide access to effective treatment and recovery services 
6.11 	that is aligned with Minnesota's model of care approach to promoting access to treatment 
6.12 	and recovery services. This includes ensuring that individuals throughout the state have 
6.13 	access to treatment and recovery services, including care coordination services; peer recovery 
6.14 	services; medication-assisted treatment and office-based opioid treatment; integrative and 
6.15 	multidisciplinary therapies; and culturally specific services; and
6.16 	(3) innovation and capacity building, including development of evidence-based practices, 
6.17 	using research and evaluation to understand which policies and programs promote efficient 
6.18 	and effective prevention, treatment, and recovery results. This also includes ensuring that 
6.19 	there are qualified providers and a comprehensive set of treatment and recovery services 
6.20 	throughout the state.
6.21 	(b) The council shall:
6.22 	(1) review local, state, and federal initiatives and funding related to prevention and 
6.23 	education, treatment, and services for individuals and families experiencing and affected 
6.24 	by opioid abuse, and promoting innovation and capacity building to address the opioid 
6.25 	addiction and overdose epidemic;
6.26 	(2) establish priorities to address the state's opioid addiction and overdose epidemic for 
6.27 	the purpose of allocating funds and consult with the commissioner of management and 
6.28 	budget to determine whether proposals are for evidence-based practices, promising practices, 
6.29 	or theory-based practices;
6.30 	(3) ensure that available funding under this section is allocated to align with existing 
6.31 	state and federal funding to achieve the greatest impact and ensure a coordinated state effort 
6.32 	to address the opioid addiction and overdose epidemic;
7.1 	(4) develop criteria and procedures to be used in awarding grants and allocating available 
7.2 	funds from the opiate epidemic response account and select proposals to receive grant 
7.3 	funding. The council is encouraged to select proposals that are promising practices or 
7.4 	theory-based practices, in addition to evidence-based practices, to help identify new 
7.5 	approaches to effective prevention, treatment, and recovery; and
7.6 	(5) in consultation with the commissioner of management and budget, and within 
7.7 	available appropriations, select from the awarded grants projects that include promising 
7.8 	practices or theory-based activities for which the commissioner of management and budget 
7.9 	shall conduct evaluations using experimental or quasi-experimental design. Grants awarded 
7.10 	to proposals that include promising practices or theory-based activities and that are selected 
7.11 	for an evaluation shall be administered to support the experimental or quasi-experimental 
7.12 	evaluation and require grantees to collect and report information that is needed to complete 
7.13 	the evaluation. The commissioner of management and budget, under section 15.08, may 
7.14 	obtain additional relevant data to support the experimental or quasi-experimental evaluation 
7.15 	studies.
7.16 		Subd. 2.Membership. (a) The council shall consist of 18 members appointed by the 
7.17 	commissioner of human services, except as otherwise specified:
7.18 	(1) two members of the house of representatives, one from the majority party appointed 
7.19 	by the speaker of the house and one from the minority party appointed by the minority 
7.20 	leader;
7.21 	(2) two members of the senate, one from the majority party appointed by the senate 
7.22 	majority leader and one from the minority party appointed by the senate minority leader;
7.23 	(3) one member appointed by the Board of Pharmacy;
7.24 	(4) one member who is a physician appointed by the Minnesota chapter of the American 
7.25 	College of Emergency Physicians;
7.26 	(5) one member representing opioid treatment programs or sober living programs;
7.27 	(6) one member who is a physician appointed by the Minnesota Hospital Association;
7.28 	(7) one member who is a physician appointed by the Minnesota Society of Addiction 
7.29 	Medicine;
7.30 	(8) one member who is a pain psychologist;
7.31 	(9) one member appointed by the Steve Rummler Hope Network;
7.32 	(10) one member appointed by the Minnesota Ambulance Association;
8.1 	(11) one member representing the Minnesota courts who is a judge or law enforcement 
8.2 	officer;
8.3 	(12) one public member who is a Minnesota resident and who has been impacted by the 
8.4 	opioid epidemic;
8.5 	(13) one member representing a manufacturer of opiates;
8.6 	(14) one member representing an Indian tribe;
8.7 	(15) the commissioner of human services or designee; and
8.8 	(16) the commissioner of health or designee.
8.9 	(b) The commissioner of human services shall coordinate appointments to provide 
8.10 	geographic diversity and shall ensure that at least one-half of council members reside outside 
8.11 	of the seven-county metropolitan area.
8.12 	(c) The council is governed by section 15.059, except that members of the council shall 
8.13 	receive no compensation other than reimbursement for expenses. Notwithstanding section 
8.14 	15.059, subdivision 6, the council shall not expire.
8.15 	(d) The chair shall convene the council at least quarterly, and may convene other meetings 
8.16 	as necessary. The chair shall convene meetings at different locations in the state to provide 
8.17 	geographic access, and shall ensure that at least one-half of the meetings are held at locations 
8.18 	outside of the seven-county metropolitan area.
8.19 	(e) The commissioner of human services shall provide staff and administrative services 
8.20 	for the advisory council.
8.21 	(f) The council is subject to chapter 13D.
8.22 		Subd. 3.Conflict of interest. Advisory council members must disclose to the council 
8.23 	and recuse themselves from voting on any matter before the council if the member has a 
8.24 	conflict of interest. A conflict of interest means a financial association that has the potential 
8.25 	to bias or have the appearance of biasing a council member's decision related to the opiate 
8.26 	epidemic response grant decision process or other council activities under this section.
8.27 		Subd. 4.Grants. (a) The commissioner of human services shall submit a report of the 
8.28 	grants proposed by the advisory council to be awarded for the upcoming fiscal year to the 
8.29 	chairs and ranking minority members of the legislative committees with jurisdiction over 
8.30 	health and human services policy and finance, by March 1 of each year, beginning March 
8.31 	1, 2020.
9.1 	(b) The commissioner of human services shall award grants from the opiate epidemic 
9.2 	response account under section 256.043. The grants shall be awarded to proposals selected 
9.3 	by the advisory council that address the priorities in subdivision 1, paragraph (a), clauses 
9.4 	(1) to (3), unless otherwise appropriated by the legislature. No more than three percent of 
9.5 	the grant amount may be used by a grantee for administration.
9.6 		Subd. 5.Reports. (a) The advisory council shall report annually to the chairs and ranking 
9.7 	minority members of the legislative committees with jurisdiction over health and human 
9.8 	services policy and finance by January 1 of each year beginning January 1, 2021, information 
9.9 	about the individual projects that receive grants and the overall role of the project in 
9.10 	addressing the opioid addiction and overdose epidemic in Minnesota. The report must 
9.11 	describe the grantees and the activities implemented, along with measurable outcomes as 
9.12 	determined by the council in consultation with the commissioner of human services and the 
9.13 	commissioner of management and budget. At a minimum, the report must include information 
9.14 	about the number of individuals who received information or treatment, the outcomes the 
9.15 	individuals achieved, and demographic information about the individuals participating in 
9.16 	the project; an assessment of the progress toward achieving statewide access to qualified 
9.17 	providers and comprehensive treatment and recovery services; and an update on the 
9.18 	evaluation implemented by the commissioner of management and budget for the promising 
9.19 	practices and theory-based projects that receive funding.
9.20 	(b) The commissioner of management and budget, in consultation with the Opiate 
9.21 	Epidemic Response Advisory Council, shall report to the chairs and ranking minority 
9.22 	members of the legislative committees with jurisdiction over health and human services 
9.23 	policy and finance when an evaluation study described in subdivision 1, paragraph (b), 
9.24 	clause (5), is complete on the promising practices or theory-based projects that are selected 
9.25 	for evaluation activities. The report shall include demographic information; outcome 
9.26 	information for the individuals in the program; the results for the program in promoting 
9.27 	recovery, employment, family reunification, and reducing involvement with the criminal 
9.28 	justice system; and other relevant outcomes determined by the commissioner of management 
9.29 	and budget that are specific to the projects that are evaluated. The report shall include 
9.30 	information about the ability of grant programs to be scaled to achieve the statewide results 
9.31 	that the grant project demonstrated.

10.1 	Sec. 5. [256.043] OPIATE EPIDEMIC RESPONSE ACCOUNT.
10.2 		Subdivision 1.Establishment. The opiate epidemic response account is established in 
10.3 	the special revenue fund in the state treasury. The registration fees assessed by the Board 
10.4 	of Pharmacy under section 151.066 shall be deposited into the account.
10.5 		Subd. 2.Use of account funds. (a) Beginning in fiscal year 2020, money in the account 
10.6 	shall be appropriated each fiscal year as specified in this subdivision.
10.7 	(b) $300,000 is appropriated to the commissioner of management and budget for 
10.8 	evaluation activities under section 256.042.
10.9 	(c) $249,000 is appropriated to the commissioner of human services for the provision 
10.10 	of administrative services to the Opiate Epidemic Response Advisory Council and for the 
10.11 	administration of the grants awarded under paragraph (f).
10.12 	(d) $33,000 is appropriated to the Board of Pharmacy for the collection of the registration 
10.13 	fees under section 151.066.
10.14 	(e) $384,000 is appropriated to the commissioner of public safety for Bureau of Criminal 
10.15 	Apprehension drug scientists and lab supplies.
10.16 	(f) $600,000 is appropriated to the commissioner of health for grants of $300,000 each 
10.17 	year to CHI St. Gabriel's Health Family Medical Center for Project Echo and $300,000 each 
10.18 	year to Hennepin Health for Project Echo.
10.19 	(g) Money remaining in the opiate epidemic response account after making the 
10.20 	appropriations required in paragraphs (b) to (f) is appropriated to the commissioner of human 
10.21 	services. The commissioner shall distribute the appropriations as follows:
10.22 	(1) at least 50 percent shall be distributed to county social service agencies to provide 
10.23 	child protection services to children and families who are affected by addiction. The 
10.24 	commissioner shall distribute this money proportionally to counties based on the number 
10.25 	of open child protection case management cases in the county using data from the previous 
10.26 	calendar year; and
10.27 	(2) the remaining money shall be awarded as specified by the Opiate Epidemic Response 
10.28 	Advisory Council as grants in accordance with section 256.042, unless otherwise appropriated 
10.29 	by the legislature.

11.1 	Sec. 6. Laws 2017, First Special Session chapter 6, article 10, section 144, is amended to 
11.2 	read:
11.3 	Sec. 144. OPIOID ABUSE PREVENTION PILOT PROJECTS.
 11.4 	(a) The commissioner of health shall establish opioid abuse prevention pilot projects in 
11.5 	geographic areas throughout the state based on the most recently available data on opioid 
11.6 	overdose and abuse rates, to reduce opioid abuse through the use of controlled substance 
11.7 	care teams and community-wide coordination of abuse-prevention initiatives. The 
11.8 	commissioner shall award grants to health care providers, health plan companies, local units 
11.9 	of government, tribal governments, or other entities to establish pilot projects.
11.10 	(b) Each pilot project must:
11.11 	(1) be designed to reduce emergency room and other health care provider visits resulting 
11.12 	from opioid use or abuse, and reduce rates of opioid addiction in the community;
11.13 	(2) establish multidisciplinary controlled substance care teams, that may consist of 
11.14 	physicians, pharmacists, social workers, nurse care coordinators, and mental health 
11.15 	professionals;
11.16 	(3) deliver health care services and care coordination, through controlled substance care 
11.17 	teams, to reduce the inappropriate use of opioids by patients and rates of opioid addiction;
11.18 	(4) address any unmet social service needs that create barriers to managing pain 
11.19 	effectively and obtaining optimal health outcomes;
11.20 	(5) provide prescriber and dispenser education and assistance to reduce the inappropriate 
11.21 	prescribing and dispensing of opioids;
11.22 	(6) promote the adoption of best practices related to opioid disposal and reducing 
11.23 	opportunities for illegal access to opioids; and
11.24 	(7) engage partners outside of the health care system, including schools, law enforcement, 
11.25 	and social services, to address root causes of opioid abuse and addiction at the community 
11.26 	level.
11.27 	(c) The commissioner shall contract with an accountable community for health that 
11.28 	operates an opioid abuse prevention project, and can document success in reducing opioid 
11.29 	use through the use of controlled substance care teams, to assist the commissioner in 
11.30 	administering this section, and to provide technical assistance to the commissioner and to 
11.31 	entities selected to operate a pilot project.
12.1 	(d) The contract under paragraph (c) shall require the accountable community for health 
12.2 	to evaluate the extent to which the pilot projects were successful in reducing the inappropriate 
12.3 	use of opioids. The evaluation must analyze changes in the number of opioid prescriptions, 
12.4 	the number of emergency room visits related to opioid use, and other relevant measures. 
12.5 	The accountable community for health shall report evaluation results to the chairs and 
12.6 	ranking minority members of the legislative committees with jurisdiction over health and 
12.7 	human services policy and finance and public safety by December 15, 2019, for projects 
12.8 	that received funding in fiscal year 2018, and by December 15, 2022, for projects that 
12.9 	received funding in fiscal year 2020.
12.10 	(e) The commissioner may award one grant that, in addition to the other requirements 
12.11 	of this section, allows a root cause approach to reduce opioid abuse in an American Indian 
12.12 	community.

12.13 	Sec. 7. OPIATE EPIDEMIC RESPONSE ADVISORY COUNCIL FIRST MEETING.
 12.14 	The commissioner of human services shall convene the first meeting of the Opiate 
12.15 	Epidemic Response Advisory Council established under Minnesota Statutes, section 256.042, 
12.16 	no later than October 1, 2019. The members shall elect a chair at the first meeting.

12.17 	Sec. 8. APPROPRIATION.
 12.18 	Before distributing the appropriations under Minnesota Statutes, section 256.043, 
12.19 	subdivision 2, paragraph (g), $1,400,000 in fiscal year 2020 is appropriated to the 
12.20 	commissioner of health from the opiate epidemic response account under Minnesota Statutes, 
12.21 	section 256.043, for opioid abuse prevention pilot projects under Laws 2017, First Special 
12.22 	Session chapter 6, article 10, section 144.

12.23 	ARTICLE 2
12.24 	OTHER OPIATE PROVISIONS

12.25 	Section 1. Minnesota Statutes 2018, section 151.01, subdivision 27, is amended to read:
12.26 		Subd. 27.Practice of pharmacy. "Practice of pharmacy" means:
12.27 	(1) interpretation and evaluation of prescription drug orders;
12.28 	(2) compounding, labeling, and dispensing drugs and devices (except labeling by a 
12.29 	manufacturer or packager of nonprescription drugs or commercially packaged legend drugs 
12.30 	and devices);
13.1 	(3) participation in clinical interpretations and monitoring of drug therapy for assurance 
13.2 	of safe and effective use of drugs, including the performance of laboratory tests that are 
13.3 	waived under the federal Clinical Laboratory Improvement Act of 1988, United States Code, 
13.4 	title 42, section 263a et seq., provided that a pharmacist may interpret the results of laboratory 
13.5 	tests but may modify drug therapy only pursuant to a protocol or collaborative practice 
13.6 	agreement;
13.7 	(4) participation in drug and therapeutic device selection; drug administration for first 
13.8 	dosage and medical emergencies; intramuscular and subcutaneous administration of drugs 
13.9 	used for the treatment of alcohol or opioid dependence and treatment of mental health 
13.10 	conditions; drug regimen reviews; and drug or drug-related research;
13.11 	(5) participation in administration of influenza vaccines to all eligible individuals six 
13.12 	years of age and older and all other vaccines to patients 13 years of age and older by written 
13.13 	protocol with a physician licensed under chapter 147, a physician assistant authorized to 
13.14 	prescribe drugs under chapter 147A, or an advanced practice registered nurse authorized to 
13.15 	prescribe drugs under section 148.235, provided that:
13.16 	(i) the protocol includes, at a minimum:
13.17 	(A) the name, dose, and route of each vaccine that may be given;
13.18 	(B) the patient population for whom the vaccine may be given;
13.19 	(C) contraindications and precautions to the vaccine;
13.20 	(D) the procedure for handling an adverse reaction;
13.21 	(E) the name, signature, and address of the physician, physician assistant, or advanced 
13.22 	practice registered nurse;
13.23 	(F) a telephone number at which the physician, physician assistant, or advanced practice 
13.24 	registered nurse can be contacted; and
13.25 	(G) the date and time period for which the protocol is valid;
13.26 	(ii) the pharmacist has successfully completed a program approved by the Accreditation 
13.27 	Council for Pharmacy Education specifically for the administration of immunizations or a 
13.28 	program approved by the board;
13.29 	(iii) the pharmacist utilizes the Minnesota Immunization Information Connection to 
13.30 	assess the immunization status of individuals prior to the administration of vaccines, except 
13.31 	when administering influenza vaccines to individuals age nine and older;
14.1 	(iv) the pharmacist reports the administration of the immunization to the Minnesota 
14.2 	Immunization Information Connection; and
14.3 	(v) the pharmacist complies with guidelines for vaccines and immunizations established 
14.4 	by the federal Advisory Committee on Immunization Practices, except that a pharmacist 
14.5 	does not need to comply with those portions of the guidelines that establish immunization 
14.6 	schedules when administering a vaccine pursuant to a valid, patient-specific order issued 
14.7 	by a physician licensed under chapter 147, a physician assistant authorized to prescribe 
14.8 	drugs under chapter 147A, or an advanced practice nurse authorized to prescribe drugs 
14.9 	under section 148.235, provided that the order is consistent with the United States Food 
14.10 	and Drug Administration approved labeling of the vaccine;
14.11 	(6) participation in the initiation, management, modification, and discontinuation of 
14.12 	drug therapy according to a written protocol or collaborative practice agreement between: 
14.13 	(i) one or more pharmacists and one or more dentists, optometrists, physicians, podiatrists, 
14.14 	or veterinarians; or (ii) one or more pharmacists and one or more physician assistants 
14.15 	authorized to prescribe, dispense, and administer under chapter 147A, or advanced practice 
14.16 	nurses authorized to prescribe, dispense, and administer under section 148.235. Any changes 
14.17 	in drug therapy made pursuant to a protocol or collaborative practice agreement must be 
14.18 	documented by the pharmacist in the patient's medical record or reported by the pharmacist 
14.19 	to a practitioner responsible for the patient's care;
14.20 	(7) participation in the storage of drugs and the maintenance of records;
14.21 	(8) patient counseling on therapeutic values, content, hazards, and uses of drugs and 
14.22 	devices;
14.23 	(9) offering or performing those acts, services, operations, or transactions necessary in 
14.24 	the conduct, operation, management, and control of a pharmacy; and
14.25 	(10) participation in the initiation, management, modification, and discontinuation of 
14.26 	therapy with opiate antagonists, as defined in section 604A.04, subdivision 1, pursuant to:
14.27 	(i) a written protocol as allowed under clause (6); or
14.28 	(ii) a written protocol with a community health board medical consultant or a practitioner 
14.29 	designated by the commissioner of health, as allowed under section 151.37, subdivision 13.

14.30 	Sec. 2. Minnesota Statutes 2018, section 152.105, subdivision 2, is amended to read:
14.31 		Subd. 2.Sheriff to maintain collection receptacle or medicine disposal program.  (a) 
14.32 	The sheriff of each county shall maintain or contract for the maintenance of at least one 
15.1 	collection receptacle or implement a medicine disposal program for the disposal of 
15.2 	noncontrolled substances, pharmaceutical controlled substances, and other legend drugs, 
15.3 	as permitted by federal law. For purposes of this section, "legend drug" has the meaning 
15.4 	given in section 151.01, subdivision 17. The collection receptacle and medicine disposal 
15.5 	program must comply with federal law. In maintaining and operating the collection receptacle
15.6 	or medicine disposal program, the sheriff shall follow all applicable provisions of Code of 
15.7 	Federal Regulations, title 21, parts 1300, 1301, 1304, 1305, 1307, and 1317, as amended 
15.8 	through May 1, 2017.
15.9 	(b) For purposes of this subdivision:
15.10 	(1) a medicine disposal program means providing to the public educational information, 
15.11 	and making materials available for safely destroying unwanted legend drugs, including but 
15.12 	not limited to drug destruction bags or drops; and
15.13 	(2) a collection receptacle means the operation and maintenance of at least one drop-off 
15.14 	receptacle.

15.15 	Sec. 3. Minnesota Statutes 2018, section 152.11, subdivision 1, is amended to read:
15.16 		Subdivision 1.General prescription requirements for controlled substances. (a) A 
15.17 	written prescription or an oral prescription reduced to writing, when issued for a controlled 
15.18 	substance in Schedule II, III, IV, or V, is void unless (1) it is written in ink and contains the 
15.19 	name and address of the person for whose use it is intended; (2) it states the amount of the 
15.20 	controlled substance to be compounded or dispensed, with directions for its use; (3) if a 
15.21 	written prescription, it contains the handwritten signature, address, and federal registry 
15.22 	number of the prescriber and a designation of the branch of the healing art pursued by the 
15.23 	prescriber; and if an oral prescription, the name and address of the prescriber and a 
15.24 	designation of the prescriber's branch of the healing art; and (4) it shows the date when 
15.25 	signed by the prescriber, or the date of acceptance in the pharmacy if an oral prescription.
15.26 	(b) An electronic prescription for a controlled substance in Schedule II, III, IV, or V is 
15.27 	void unless it complies with the standards established pursuant to section 62J.497 and with 
15.28 	those portions of Code of Federal Regulations, title 21, parts 1300, 1304, 1306, and 1311, 
15.29 	that pertain to electronic prescriptions.
15.30 	(c) A prescription for a controlled substance in Schedule II, III, IV, or V that is transmitted 
15.31 	by facsimile, either computer to facsimile machine or facsimile machine to facsimile machine, 
15.32 	is void unless it complies with the applicable requirements of Code of Federal Regulations, 
15.33 	title 21, part 1306.
16.1 	(d) Every licensed pharmacy that dispenses a controlled substance prescription shall 
16.2 	retain the original prescription in a file for a period of not less than two years, open to 
16.3 	inspection by any officer of the state, county, or municipal government whose duty it is to 
16.4 	aid and assist with the enforcement of this chapter. An original electronic or facsimile 
16.5 	prescription may be stored in an electronic database, provided that the database provides a 
16.6 	means by which original prescriptions can be retrieved, as transmitted to the pharmacy, for 
16.7 	a period of not less than two years.
16.8 	(e) Every licensed pharmacy shall distinctly label the container in which a controlled 
16.9 	substance is dispensed with the directions contained in the prescription for the use of that 
16.10 	controlled substance.
16.11 	(f) No prescription for an opiate or narcotic pain reliever listed in Schedules II through 
16.12 	IV of section 152.02 shall be dispensed more than 30 days after the date on which the 
16.13 	prescription was issued. After 30 days from the date of issuance of the prescription, no 
16.14 	additional authorizations may be accepted for that prescription. If continued therapy is 
16.15 	necessary, a new prescription must be issued by the prescriber.

16.16 	Sec. 4. Minnesota Statutes 2018, section 152.11, subdivision 2, is amended to read:
16.17 		Subd. 2. Prescription requirements for Schedule III or IV controlled substances. No 
16.18 	person may dispense a controlled substance included in Schedule III or IV of section 152.02
16.19 	without a prescription issued, as permitted under subdivision 1, by a doctor of medicine, a 
16.20 	doctor of osteopathic medicine licensed to practice medicine, a doctor of dental surgery, a 
16.21 	doctor of dental medicine, a doctor of podiatry, a doctor of optometry limited to Schedule 
16.22 	IV, or a doctor of veterinary medicine, lawfully licensed to prescribe in this state or from 
16.23 	a practitioner licensed to prescribe controlled substances by the state in which the prescription 
16.24 	is issued, and having a current federal drug enforcement administration registration number. 
16.25 	Such prescription may not be dispensed or refilled except with the documented consent of 
16.26 	the prescriber, and in no event more than six months after the date on which such prescription 
16.27 	was issued and no such prescription may be refilled more than five times.

16.28 	Sec. 5. Minnesota Statutes 2018, section 152.11, subdivision 4, is amended to read:
16.29 		Subd. 4.Limit on quantity of opiates prescribed for acute dental and ophthalmic 
16.30 	pain. (a) When used for the treatment of acute pain, prescriptions for opiates or narcotic 
16.31 	pain relievers listed in Schedules II through IV in section 152.02 shall not exceed a seven-day 
16.32 	supply for an adult and shall not exceed a five-day supply for a minor under 18 years of 
16.33 	age.
17.1 	(a) (b) Notwithstanding paragraph (a), when used for the treatment of acute dental pain, 
17.2 	including acute pain associated with wisdom teeth extraction surgery or acute pain associated 
17.3 	with refractive surgery, prescriptions for opiate or narcotic pain relievers listed in Schedules 
17.4 	II through IV of section 152.02 shall not exceed a four-day supply. The quantity prescribed 
17.5 	shall be consistent with the dosage listed in the professional labeling for the drug that has 
17.6 	been approved by the United States Food and Drug Administration.
17.7 	(b) (c) For the purposes of this subdivision, "acute pain" means pain resulting from 
17.8 	disease, accidental or intentional trauma, surgery, or another cause, that the practitioner 
17.9 	reasonably expects to last only a short period of time. Acute pain does not include chronic 
17.10 	pain or pain being treated as part of cancer care, palliative care, or hospice or other end-of-life 
17.11 	care.
17.12 	(c) Notwithstanding paragraph (a), if in the professional clinical judgment of a practitioner 
17.13 	more than a four-day supply of a prescription listed in Schedules II through IV of section 
17.14 	152.02 is required to treat a patient's acute pain, the practitioner may issue a prescription 
17.15 	for the quantity needed to treat such acute pain.
17.16 	(d) Notwithstanding paragraph (a) or (b), if, in the professional clinical judgment of a 
17.17 	practitioner, more than the limit specified in paragraph (a) or (b) is required to treat a patient's 
17.18 	acute pain, the practitioner may issue a prescription for the quantity needed to treat the 
17.19 	patient's acute pain.

17.20 	Sec. 6. Minnesota Statutes 2018, section 152.126, subdivision 6, is amended to read:
17.21 		Subd. 6.Access to reporting system data. (a) Except as indicated in this subdivision, 
17.22 	the data submitted to the board under subdivision 4 is private data on individuals as defined 
17.23 	in section 13.02, subdivision 12, and not subject to public disclosure.
17.24 	(b) Except as specified in subdivision 5, the following persons shall be considered 
17.25 	permissible users and may access the data submitted under subdivision 4 in the same or 
17.26 	similar manner, and for the same or similar purposes, as those persons who are authorized 
17.27 	to access similar private data on individuals under federal and state law:
17.28 	(1) a prescriber or an agent or employee of the prescriber to whom the prescriber has 
17.29 	delegated the task of accessing the data, to the extent the information relates specifically to 
17.30 	a current patient, to whom the prescriber is:
17.31 	(i) prescribing or considering prescribing any controlled substance;
17.32 	(ii) providing emergency medical treatment for which access to the data may be necessary;
18.1 	(iii) providing care, and the prescriber has reason to believe, based on clinically valid 
18.2 	indications, that the patient is potentially abusing a controlled substance; or
18.3 	(iv) providing other medical treatment for which access to the data may be necessary 
18.4 	for a clinically valid purpose and the patient has consented to access to the submitted data, 
18.5 	and with the provision that the prescriber remains responsible for the use or misuse of data 
18.6 	accessed by a delegated agent or employee;
18.7 	(2) a dispenser or an agent or employee of the dispenser to whom the dispenser has 
18.8 	delegated the task of accessing the data, to the extent the information relates specifically to 
18.9 	a current patient to whom that dispenser is dispensing or considering dispensing any 
18.10 	controlled substance and with the provision that the dispenser remains responsible for the 
18.11 	use or misuse of data accessed by a delegated agent or employee;
18.12 	(3) a licensed pharmacist who is providing pharmaceutical care for which access to the 
18.13 	data may be necessary to the extent that the information relates specifically to a current 
18.14 	patient for whom the pharmacist is providing pharmaceutical care: (i) if the patient has 
18.15 	consented to access to the submitted data; or (ii) if the pharmacist is consulted by a prescriber 
18.16 	who is requesting data in accordance with clause (1);
18.17 	(4) an individual who is the recipient of a controlled substance prescription for which 
18.18 	data was submitted under subdivision 4, or a guardian of the individual, parent or guardian 
18.19 	of a minor, or health care agent of the individual acting under a health care directive under 
18.20 	chapter 145C. For purposes of this clause, access by individuals includes persons in the 
18.21 	definition of an individual under section 13.02;
18.22 	(5) personnel or designees of a health-related licensing board listed in section 214.01, 
18.23 	subdivision 2, or of the Emergency Medical Services Regulatory Board, assigned to conduct 
18.24 	a bona fide investigation of a complaint received by that board that alleges that a specific 
18.25 	licensee is impaired by use of a drug for which data is collected under subdivision 4, has 
18.26 	engaged in activity that would constitute a crime as defined in section 152.025, or has 
18.27 	engaged in the behavior specified in subdivision 5, paragraph (a);
18.28 	(6) personnel of the board engaged in the collection, review, and analysis of controlled 
18.29 	substance prescription information as part of the assigned duties and responsibilities under 
18.30 	this section;
18.31 	(7) authorized personnel of a vendor under contract with the state of Minnesota who are 
18.32 	engaged in the design, implementation, operation, and maintenance of the prescription 
18.33 	monitoring program as part of the assigned duties and responsibilities of their employment, 
18.34 	provided that access to data is limited to the minimum amount necessary to carry out such 
19.1 	duties and responsibilities, and subject to the requirement of de-identification and time limit 
19.2 	on retention of data specified in subdivision 5, paragraphs (d) and (e);
19.3 	(8) federal, state, and local law enforcement authorities acting pursuant to a valid search 
19.4 	warrant;
19.5 	(9) personnel of the Minnesota health care programs assigned to use the data collected 
19.6 	under this section to identify and manage recipients whose usage of controlled substances 
19.7 	may warrant restriction to a single primary care provider, a single outpatient pharmacy, and 
19.8 	a single hospital;
19.9 	(10) personnel of the Department of Human Services assigned to access the data pursuant 
19.10 	to paragraph (i);
19.11 	(11) personnel of the health professionals services program established under section 
19.12 	214.31, to the extent that the information relates specifically to an individual who is currently 
19.13 	enrolled in and being monitored by the program, and the individual consents to access to 
19.14 	that information. The health professionals services program personnel shall not provide this 
19.15 	data to a health-related licensing board or the Emergency Medical Services Regulatory 
19.16 	Board, except as permitted under section 214.33, subdivision 3.; and
19.17 	For purposes of clause (4), access by an individual includes persons in the definition of 
19.18 	an individual under section 13.02; and
19.19 	(12) personnel or designees of a health-related licensing board listed in section 214.01, 
19.20 	subdivision 2, assigned to conduct a bona fide investigation of a complaint received by that 
19.21 	board that alleges that a specific licensee is inappropriately prescribing controlled substances 
19.22 	as defined in this section.
19.23 	(c) By July 1, 2017, every prescriber licensed by a health-related licensing board listed 
19.24 	in section 214.01, subdivision 2, practicing within this state who is authorized to prescribe 
19.25 	controlled substances for humans and who holds a current registration issued by the federal 
19.26 	Drug Enforcement Administration, and every pharmacist licensed by the board and practicing 
19.27 	within the state, shall register and maintain a user account with the prescription monitoring 
19.28 	program. Data submitted by a prescriber, pharmacist, or their delegate during the registration 
19.29 	application process, other than their name, license number, and license type, is classified 
19.30 	as private pursuant to section 13.02, subdivision 12.
19.31 	(d) Notwithstanding paragraph (b), beginning January 1, 2021, a prescriber or an agent 
19.32 	or employee of the prescriber to whom the prescriber has delegated the task of accessing 
20.1 	the data, must access the data submitted under subdivision 4 to the extent the information 
20.2 	relates specifically to the patient:
20.3 	(1) before the prescriber issues an initial prescription order for a Schedules II through 
20.4 	IV opiate controlled substance to the patient; and
20.5 	(2) at least once every three months for patients receiving an opiate for treatment of 
20.6 	chronic pain or participating in medically assisted treatment for an opioid addiction.
20.7 	(e) Paragraph (d) does not apply if:
20.8 	(1) the patient is receiving hospice care;
20.9 	(2) the patient is being treated for pain due to cancer or the treatment of cancer;
20.10 	(3) the prescription order is for a number of doses that is intended to last the patient five 
20.11 	days or less and is not subject to a refill;
20.12 	(4) the prescriber and patient have an ongoing provider/patient relationship of a duration 
20.13 	longer than one year;
20.14 	(5) the prescription order is issued within 14 days following surgery or three days 
20.15 	following oral surgery;
20.16 	(6) the controlled substance is prescribed or administered to a patient who is admitted 
20.17 	to an inpatient hospital;
20.18 	(7) the controlled substance is lawfully administered by injection, ingestion, or any other 
20.19 	means to the patient by the prescriber, a pharmacist, or by the patient at the direction of a 
20.20 	prescriber and in the presence of the prescriber or pharmacist;
20.21 	(8) due to a medical emergency, it is not possible for the prescriber to review the data 
20.22 	before the prescriber issues the prescription order for the patient; or
20.23 	(9) the prescriber is unable to access the data due to operational or other technological 
20.24 	failure of the program so long as the prescriber reports the failure to the board.
20.25 	(f) Only permissible users identified in paragraph (b), clauses (1), (2), (3), (6), (7), (9), 
20.26 	and (10), may directly access the data electronically. No other permissible users may directly 
20.27 	access the data electronically. If the data is directly accessed electronically, the permissible 
20.28 	user shall implement and maintain a comprehensive information security program that 
20.29 	contains administrative, technical, and physical safeguards that are appropriate to the user's 
20.30 	size and complexity, and the sensitivity of the personal information obtained. The permissible 
20.31 	user shall identify reasonably foreseeable internal and external risks to the security, 
20.32 	confidentiality, and integrity of personal information that could result in the unauthorized 
21.1 	disclosure, misuse, or other compromise of the information and assess the sufficiency of 
21.2 	any safeguards in place to control the risks.
21.3 	(e) (g) The board shall not release data submitted under subdivision 4 unless it is provided 
21.4 	with evidence, satisfactory to the board, that the person requesting the information is entitled 
21.5 	to receive the data.
21.6 	(f) (h) The board shall maintain a log of all persons who access the data for a period of 
21.7 	at least three years and shall ensure that any permissible user complies with paragraph (c) 
21.8 	prior to attaining direct access to the data.
21.9 	(g) (i) Section 13.05, subdivision 6, shall apply to any contract the board enters into 
21.10 	pursuant to subdivision 2. A vendor shall not use data collected under this section for any 
21.11 	purpose not specified in this section.
21.12 	(h) (j) The board may participate in an interstate prescription monitoring program data 
21.13 	exchange system provided that permissible users in other states have access to the data only 
21.14 	as allowed under this section, and that section 13.05, subdivision 6, applies to any contract 
21.15 	or memorandum of understanding that the board enters into under this paragraph.
21.16 	(i) (k) With available appropriations, the commissioner of human services shall establish 
21.17 	and implement a system through which the Department of Human Services shall routinely 
21.18 	access the data for the purpose of determining whether any client enrolled in an opioid 
21.19 	treatment program licensed according to chapter 245A has been prescribed or dispensed a 
21.20 	controlled substance in addition to that administered or dispensed by the opioid treatment 
21.21 	program. When the commissioner determines there have been multiple prescribers or multiple 
21.22 	prescriptions of controlled substances, the commissioner shall:
21.23 	(1) inform the medical director of the opioid treatment program only that the 
21.24 	commissioner determined the existence of multiple prescribers or multiple prescriptions of 
21.25 	controlled substances; and
21.26 	(2) direct the medical director of the opioid treatment program to access the data directly, 
21.27 	review the effect of the multiple prescribers or multiple prescriptions, and document the 
21.28 	review.
21.29 	If determined necessary, the commissioner of human services shall seek a federal waiver 
21.30 	of, or exception to, any applicable provision of Code of Federal Regulations, title 42, section 
21.31 	2.34, paragraph (c), prior to implementing this paragraph.
21.32 	(j) (l) The board shall review the data submitted under subdivision 4 on at least a quarterly 
21.33 	basis and shall establish criteria, in consultation with the advisory task force, for referring 
22.1 	information about a patient to prescribers and dispensers who prescribed or dispensed the 
22.2 	prescriptions in question if the criteria are met.

22.3 	Sec. 7. Minnesota Statutes 2018, section 152.126, subdivision 10, is amended to read:
22.4 		Subd. 10.Funding. (a) The board may seek grants and private funds from nonprofit 
22.5 	charitable foundations, the federal government, and other sources to fund the enhancement 
22.6 	and ongoing operations of the prescription monitoring program established under this section. 
22.7 	Any funds received shall be appropriated to the board for this purpose. The board may not 
22.8 	expend funds to enhance the program in a way that conflicts with this section without seeking 
22.9 	approval from the legislature.
22.10 	(b) Notwithstanding any other section, the administrative services unit for the 
22.11 	health-related licensing boards shall apportion between the Board of Medical Practice, the 
22.12 	Board of Nursing, the Board of Dentistry, the Board of Podiatric Medicine, the Board of 
22.13 	Optometry, the Board of Veterinary Medicine, and the Board of Pharmacy an amount to be 
22.14 	paid through fees by each respective board. The amount apportioned to each board shall 
22.15 	equal each board's share of the annual appropriation to the Board of Pharmacy from the 
22.16 	state government special revenue fund for operating the prescription monitoring program 
22.17 	under this section. Each board's apportioned share shall be based on the number of prescribers 
22.18 	or dispensers that each board identified in this paragraph licenses as a percentage of the 
22.19 	total number of prescribers and dispensers licensed collectively by these boards. Each 
22.20 	respective board may adjust the fees that the boards are required to collect to compensate 
22.21 	for the amount apportioned to each board by the administrative services unit.
22.22 	(c) The board has the authority to modify its contract with its vendor as provided in 
22.23 	subdivision 2, to authorize that vendor to provide a service to prescribers and pharmacies 
22.24 	that allows them to access prescription monitoring program data from within the electronic 
22.25 	health record system or pharmacy software used by those prescribers and pharmacists. 
22.26 	Beginning July 1, 2019, the board has the authority to collect an annual fee from each 
22.27 	prescriber or pharmacist who accesses prescription monitoring program data through the 
22.28 	service offered by the vendor. The annual fee collected must not exceed $50 per user. The 
22.29 	fees collected by the board under this paragraph shall be deposited in the state government 
22.30 	special revenue fund and are appropriated to the board for the purposes of this paragraph.

23.1 	Sec. 8. Minnesota Statutes 2018, section 214.12, is amended by adding a subdivision to 
23.2 	read:
23.3 		Subd. 6.Opioid and controlled substances prescribing. (a) The Board of Medical 
23.4 	Practice, the Board of Nursing, the Board of Dentistry, the Board of Optometry, and the 
23.5 	Board of Podiatric Medicine shall require that licensees with the authority to prescribe 
23.6 	controlled substances obtain at least two hours of continuing education credit on best practices 
23.7 	in prescribing opioids and controlled substances, as part of the continuing education 
23.8 	requirements for licensure renewal. Licensees shall not be required to complete more than 
23.9 	two credit hours of continuing education on best practices in prescribing opioids and 
23.10 	controlled substances before this subdivision expires. Continuing education credit on best 
23.11 	practices in prescribing opioids and controlled substances must meet board requirements.
23.12 	(b) This subdivision expires January 1, 2024.

23.13 	EFFECTIVE DATE. This section is effective January 1, 2020.

23.14 	Sec. 9. OPIOID OVERDOSE REDUCTION PILOT PROGRAM.
 23.15 		Subdivision 1.Establishment. The commissioner of health shall provide grants to 
23.16 	ambulance services to fund activities by community paramedic teams to reduce opioid 
23.17 	overdoses in the state. Under this pilot program, ambulance services shall develop and 
23.18 	implement projects in which community paramedics connect with patients who are discharged 
23.19 	from a hospital or emergency department following an opioid overdose episode, develop 
23.20 	personalized care plans for those patients in consultation with the ambulance service medical 
23.21 	director, and provide follow-up services to those patients.
23.22 		Subd. 2.Priority areas; services. (a) In a project developed under this section, an 
23.23 	ambulance service must target community paramedic team services to portions of the service 
23.24 	area with high levels of opioid use, high death rates from opioid overdoses, and urgent needs 
23.25 	for interventions.
23.26 	(b) In a project developed under this section, a community paramedic team shall:
23.27 	(1) provide services to patients released from a hospital or emergency department 
23.28 	following an opioid overdose episode and place priority on serving patients who were 
23.29 	administered the opiate antagonist naloxone hydrochloride by emergency medical services 
23.30 	personnel in response to a 911 call during the opioid overdose episode;
23.31 	(2) provide the following evaluations during an initial home visit: (i) a home safety 
23.32 	assessment including whether there is a need to dispose of prescription drugs that are expired 
24.1 	or no longer needed; (ii) medication compliance; (iii) an HIV risk assessment; (iv) instruction 
24.2 	on the use of naloxone hydrochloride; and (v) a basic needs assessment;
24.3 	(3) provide patients with health assessments, chronic disease monitoring and education, 
24.4 	and assistance in following hospital discharge orders; and
24.5 	(4) work with a multidisciplinary team to address the overall physical and mental health 
24.6 	needs of patients and health needs related to substance use disorder treatment.
24.7 	(c) An ambulance service receiving a grant under this section may use grant funds to 
24.8 	cover the cost of evidence-based training in opioid addiction and recovery treatment.
24.9 		Subd. 3.Evaluation. An ambulance service that receives a grant under this section shall 
24.10 	evaluate the extent to which the project was successful in reducing the number of opioid 
24.11 	overdoses and opioid overdose deaths among patients who received services and in reducing 
24.12 	the inappropriate use of opioids by patients who received services. The commissioner of 
24.13 	health shall develop specific evaluation measures and reporting timelines for ambulance 
24.14 	services receiving grants. Ambulance services shall submit the information required by the 
24.15 	commissioner to the commissioner and the commissioner shall submit a summary of the 
24.16 	information reported by the ambulance services to the chairs and ranking minority members 
24.17 	of the legislative committees with jurisdiction over health and human services by December 
24.18 	1, 2020.

24.19 	Sec. 10. APPROPRIATION.
 24.20 	(a) $1,000,000 in fiscal year 2020 is appropriated from the general fund to the 
24.21 	commissioner of health for the opioid overdose reduction pilot program. This appropriation 
24.22 	is available until the end of the biennium. Of this appropriation, the commissioner may use 
24.23 	up to $50,000 to administer the program.
24.24 	(b) $150,000 is appropriated in fiscal year 2020 from the general fund to the commissioner 
24.25 	of health to award through a competitive request for proposal process a grant to an 
24.26 	organization to conduct a statewide inventory of nonnarcotic pain management, prevention, 
24.27 	and resiliency resources available through community organizations, health clinics, and 
24.28 	health care systems. By January 15, 2021, the commissioner shall submit the completed 
24.29 	inventory to the chairs and ranking minority members of the house of representatives and 
24.30 	senate committees with jurisdiction over health and human services policy and finance. 
24.31 	This is a onetime appropriation.